Recent News

• 11.04.2026 - AC Immune Third Quarter 2026 Financial and Corporate Update
• 09.23.2026 - AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
• 08.20.2026 - AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
• 08.11.2026 - AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
• 08.05.2026 - AC Immune First Half 2026 Financial and Corporate Update
• 07.07.2026 - AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
• 06.30.2026 - AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease
• 04.30.2026 - AC Immune First Quarter 2026 Financial and Corporate Updates
• 03.13.2026 - AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
• 10.28.2025 - AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board

Recent Filings

• 11.04.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.04.2026 - EX-99.1 EX-99.1
• 10.09.2026 - 3/A Initial statement of beneficial ownership of securities
• 10.09.2026 - 3 Initial statement of beneficial ownership of securities
• 10.02.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.23.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.23.2026 - EX-99.1 EX-99.1
• 09.03.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.03.2026 - EX-99.1 EX-99.1
• 08.20.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]